AIkido Pharma to Attend the Alzheimer's Association International Conference

Rhea-AI Summary

AIkido Pharma Inc. (Nasdaq: AIKI) will participate in the Alzheimer's Association International Conference (AAIC 2021) in Denver from July 26-30, 2021. The AAIC is a key event in dementia science, gathering leading researchers and clinicians to discuss advancements in prevention, treatment, and diagnosis of Alzheimer's disease. CEO Anthony Hayes emphasized the importance of addressing unmet medical needs in dementia. AIkido Pharma is known for its diverse portfolio in small-molecule anti-cancer therapeutics and is expanding its focus on innovative drug platforms.

NEW YORK, July 13, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced it will attend the Alzheimer's Association International Conference in Denver, July 26-30, 2021. ("AAIC 2021") The AAIC is the largest and most influential international meeting dedicated to advancing dementia science. Each year, AAIC convenes the world's leading basic science and clinical researchers, next-generation investigators, clinicians, and the care research community to share research discoveries that will lead to methods of prevention and treatment and improvements in the diagnosis of Alzheimer's disease. (https://www.alz.org/aaic/overview.asp).

Anthony Hayes, CEO of AIkido stated, "We believe that advancing the science of dementia is important and the treatment of the disease has significant unmet medical needs.  We are excited to be a part of this conference as we continue to work towards greater diversification of the Company."

About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics.  The Company's platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology.  The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:      

Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido Pharma Inc.:   

Phone: 212-745-1373
Email: investorrelations@aikidopharma.com 
www.aikidopharma.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/aikido-pharma-to-attend-the-alzheimers-association-international-conference-301332594.html

SOURCE AIkido Pharma Inc.

FAQ

What is AIkido Pharma's participation in AAIC 2021?

AIkido Pharma will attend the Alzheimer's Association International Conference in Denver from July 26-30, 2021, to engage with leading researchers in dementia science.

What are the dates for AAIC 2021?

The Alzheimer's Association International Conference will take place from July 26-30, 2021.

Who commented on AIkido Pharma's focus on dementia research?

CEO Anthony Hayes commented on the importance of advancing dementia science and addressing unmet medical needs in the field.

What is AIkido Pharma known for?

AIkido Pharma is known for its diverse portfolio of small-molecule anti-cancer therapeutics and is expanding into dementia research.

What type of company is AIkido Pharma?

AIkido Pharma is a biotechnology company focusing on developing therapeutic drug platforms addressing various medical needs, including oncology and viral infections.